netFormulary

Lancashire and South Cumbria
Formulary

4 Central nervous system

This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/

04-09-01 Levodopa

Co-Beneldopa Madopar^®

Formulary

Capsules 62.5mg (12.5/50), 125mg (25/100), 250mg (50/200)
Dispersible tablets 62.5mg (12.5/50), 125mg(25/100)
m/r capsules 125mg (25/100)

Co-Careldopa Sinemet^®

Formulary

Tablets 62.5mg (12.5/50), 110mg (10/100)
Tablets 125mg (25/100)
Tablets 250mg (50/200)
m/r tablets 125mg (25/100)
m/r tablets 250mg (50/200)

Co-Careldopa and Entacapone

Formulary

Tablets - all strengths available

Foslevodopa�Foscarbidopa Produodopa^®

Formulary

Solution for infusion 240mg/ml + 12mg/ml

NICE TA934: Foslevodopa�foscarbidopa for treating advanced Parkinson�s with motor symptoms

Levodopa-Carbidopa- Entacapone Intestinal Gel (LECIG)

Formulary

Treatment with LECIG for Parkinson’s Disease may be delivered and managed through any acute provider trust which treats patients with Parkinson’s disease under either neurology or elderly care services. Eligibility must be determined through a specialist Parkinson’s clinician in an agreed networked approach with a specialist Parkinson's service in a regional specialised neurology centre. This may be through direct clinical assessment by clinicians with appropriate expertise within the network or through a Parkinson’s disease MDT arrangement managed through a specialised neurology centre.

Levodopa-Carbidopa Intestinal Gel (LCIG)

Formulary

Treatment with LCIG for Parkinson’s Disease may be delivered and managed through any acute provider trust which treats patients with Parkinson’s disease under either neurology or elderly care services. Eligibility must be determined through a specialist Parkinson’s clinician in an agreed networked approach with a specialist Parkinson's service in a regional specialised neurology centre. This may be through direct clinical assessment by clinicians with appropriate expertise within the network or through a Parkinson’s disease MDT arrangement managed through a specialised neurology centre.

Links